First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring - 26/07/17
, Gabriela Vazquez-Benitez, PhD 1, Paul A. Romitti, PhD 2, Allison L. Naleway, PhD 3, T. Craig Cheetham, PharmD 4, Heather S. Lipkind, MD, MS 5, Nicola P. Klein, MD, PhD 6, Grace Lee, MD, MPH 7, Michael L. Jackson, PhD, MPH 8, Simon J. Hambidge, MD, PhD 9, Natalie McCarthy, MPH 10, Frank DeStefano, MD, MPH 10, James D. Nordin, MD, MPH 1for the
Vaccine Safety Datalink
Abstract |
Objective |
To examine risks for major structural birth defects in infants after first trimester inactivated influenza vaccine (IIV) exposures.
Study design |
In this observational study, we used electronic health data from 7 Vaccine Safety Datalink sites to examine risks for selected major structural defects in infants after maternal IIV exposure. Vaccine exposures for women with continuous insurance enrollment through pregnancy who delivered singleton live births between 2004 and 2013 were identified from standardized files. Infants with continuous insurance enrollment were followed to 1 year of age. We excluded mother–infant pairs with other exposures that potentially increased their background risk for birth defects. Selected cardiac, orofacial or respiratory, neurologic, ophthalmologic or otologic, gastrointestinal, genitourinary and muscular or limb defects were identified from diagnostic codes in infant medical records using validated algorithms. Propensity score adjusted generalized estimating equations were used to estimate prevalence ratios (PRs).
Results |
We identified 52 856 infants with maternal first trimester IIV exposure and 373 088 infants whose mothers were unexposed to IIV during first trimester. Prevalence (per 100 live births) for selected major structural birth defects was 1.6 among first trimester IIV exposed versus 1.5 among unexposed mothers. The adjusted PR was 1.02 (95% CI 0.94-1.10). Organ system-specific PRs were similar to the overall PR.
Conclusion |
First trimester maternal IIV exposure was not associated with an increased risk for selected major structural birth defects in this large cohort of singleton live births.
Le texte complet de cet article est disponible en PDF.Abbreviations : ICD-9, IIV, PD, PR, VSD
Plan
| Funded by the Centers for Disease Control and Prevention (200-2012-53526 [to E.K]). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. N.K. receives research support from GlaxoSmithKline, Sanofi Pasteur, Pfizer, Merck, and Protein Science, and MedImmune. A.N. receives research support from GlaxoSmithKline, Pfizer, Merck, and MedImmune. T.C. receives research support from Bristol-Myers Squibb. M.J. receives research support from Sanofi Pasteur. The other authors declare no conflicts of interest. |
Vol 187
P. 234 - août 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
